Figures & data
Table 1 CD markers used for MP measurements
Figure 1 FC gating strategy used for MP measurement.
Notes: (A–C) MP size gate was determined using 0.3 µm, 0.5 µm, and 0.9 µm FITC-labeled polystyrene MBs. The lower side of the gate was set below 0.5 µm bead as a threshold, because the 0.3 µm and 0.5 µm bead histogram displayed an overlap indicating that the cytometer would not be able to discriminate individual MPs between these size ranges. The upper side of the gate was set at the upper and right sides of the 0.9 µm bead cloud. In this MP gate, the buffer and the sample containing MPs can be clearly distinguished. (D–G) MPs were defined as Annexin V+ events in the size gate, with fluorescence intensity above isotype control and the sample-free buffer.
Abbreviations: Cy5, CyChrome (PE-Cy5 conjugate); FC, flow cytometry; FITC, fluorescein isothiocyanate; FS, forward scatter; Iso, isotype; MB, microbeads; MP, microparticle; PE, phycoerythrin.; SS, side scatter.
Abbreviations: Cy5, CyChrome (PE-Cy5 conjugate); FC, flow cytometry; FITC, fluorescein isothiocyanate; FS, forward scatter; Iso, isotype; MB, microbeads; MP, microparticle; PE, phycoerythrin.; SS, side scatter.
Table 2 Demographic and clinical data of COPD patients
Table 3 Number of MPs in control subjects and patients with stable and AECOPD
Figure 2 Comparison of PAC1+ MPs in patients with GOLD stage I–II vs stage III–IV.
Note: PAC1+ MP numbers are significantly increased in patients with GOLD stage III–IV compared to patients with GOLD stage I–II (data are presented as median and 25–75th percentiles, Mann–Whitney test, P=0.031).
Abbreviation: MPs, microparticles.
Abbreviation: MPs, microparticles.
Table S1 Individual antibody cocktails used for MP measurements